IBB Fees and Costs — iShares Biotechnology ETF
Data updated: 2026-08-25
The net expense ratio is 0.44%. There are no sales loads or redemption fees. In fiscal 2026 the fund paid $621K in broker commissions, 0.0092% of average net assets, and portfolio turnover was 18%.
IBB Fees and Expenses
Annual operating expenses and sales charges of IBB. Prospectus, as of March 31, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 0.44% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.00% |
| Gross expense ratio | 0.44% |
| Fee waiver | — |
| Net expense ratio | 0.44% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | No |
| Fees waived or reduced during the year | No |
| Waived fees subject to recoupment | No |
IBB Costs Over Time
On $10,000 invested in IBB, assuming 5% a year before costs, total costs come to $284 over 5 years, cutting the return by 0.47% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.44%) | $46 | $145 | $253 |
| Trading costs (broker commissions) | $1 | $3 | $5 |
| Lost growth on money paid in costs | $0 | $7 | $26 |
| Total costs | $47 | $155 | $284 |
| Value after costs | $10,453 | $11,421 | $12,479 |
| Impact on return, per year | 0.47% | 0.47% | 0.47% |
IBB Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending March 31, 2026.
- Explicit cost rate (commissions ÷ average net assets): 0.0092%
- Total broker commissions: $621K
- Bought from dealers (principal trades, not a cost): $21.5B
- Portfolio turnover (prospectus): 18%
- Securities on loan, average value: $675.5M
- Net income from securities lending: $5.9M (0.088% of average net assets)
IBB Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| BNP Paribas Securities Corp. | $125K | 22.22% |
| Goldman Sachs & Co. LLC | $89K | 15.84% |
| TD SECURITIES (USA) LLC | $66K | 11.76% |
| Cantor Fitzgerald & Co. | $61K | 10.88% |
| BofA Securities, Inc. | $52K | 9.25% |
| UBS Securities LLC | $46K | 8.21% |
| Jefferies LLC | $40K | 7.05% |
| Pershing LLC | $37K | 6.63% |
| Morgan Stanley & Co. LLC | $31K | 5.48% |
| Wells Fargo Securities, LLC | $15K | 2.68% |
IBB Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| National Securities Clearing Corp. | $20.6B | 95.98% |
| BlackRock Liquidity Funds T-Fund | $859.8M | 4.00% |
| Goldman Sachs & Co. LLC | $1.4M | 0.01% |
| Citigroup Global Markets Inc. | $642K | 0.00% |
| Morgan Stanley & Co. LLC | $558K | 0.00% |
| BNP Paribas Securities Corp. | $294K | 0.00% |
| BofA Securities, Inc. | $292K | 0.00% |
| RBC Capital Markets, LLC | $209K | 0.00% |
| ABN AMRO Clearing Chicago LLC | $185K | 0.00% |
| Citadel Securities LLC | $178K | 0.00% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.